4.7 Article

CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach

Journal

JOURNAL OF NANOBIOTECHNOLOGY
Volume 21, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12951-023-01900-8

Keywords

Vaccine; CpG ODN; Neoantigen; CD16; Immunotherapy

Ask authors/readers for more resources

Combinatorial immunotherapy strategies using engineered nanoformulations and toll-like receptor 9 agonist CpG ODN have shown great promise for cancer therapy. In this study, a self-assembled nanoparticle called CNPs was developed to deliver CpG ODN into dendritic cells, effectively stimulating immune response. Additionally, the CNPs-adjuvanted vaccine based on melanoma antigens and neoantigens exhibited both cellular and humoral immune responses, inhibiting tumor growth. CD16 CAR-T cells showed potential as a synergistic strategy for solid tumor immunotherapy.
BackgroundCombinatorial immunotherapy strategies for enhancing the responsiveness of immune system have shown great promise for cancer therapy. Engineered nanoformulation incorporated toll-like receptor (TLR) 9 agonist CpG ODN has shown more positive results in suppressing tumor growth and can significantly enhance other immunotherapy activity with combinatorial effects due to the innate and adaptive immunostimulatory effects of CpG.ResultsIn the present work, protamine sulfate (PS) and carboxymethyl beta-glucan (CMG) were used as nanomaterials to form nanoparticles through a self-assembly approach for CpG ODN encapsulation to generate CpG ODN-loaded nano-adjuvant (CNPs), which was subsequently mixed with the mixture of mouse melanoma-derived antigens of tumor cell lysates (TCL) and neoantigens to develop vaccine for anti-tumor immunotherapy. The obtained results showed that CNPs was able to effectively deliver CpG ODN into murine bone marrow-derived dendritic cells (DC) in vitro, and remarkably stimulate the maturation of DC cells with proinflammatory cytokine secretion. In addition, in vivo analysis showed that CNPs enhanced anti-tumor activity of PD1 antibody and CNPs-adjuvanted vaccine based on the mixture antigens of melanoma TCL and melanoma-specific neoantigen could not only induce anti-melanoma cellular immune responses, but also elicit melanoma specific humoral immune responses, which significantly inhibited xenograft tumor growth. Furthermore, CD16 CAR-T cells were generated by expressing CD16-CAR in CD3(+)CD8(+) murine T cells.ConclusionOur results eventually showed that anti-melanoma antibodies induced by CNPs-adjuvanted TCL vaccines were able to collaborate with CD16-CAR-T cells to generate an enhanced targeted anti-tumor effects through ADCC (antibody dependent cell cytotoxicity) approach. CD16 CAR-T cells has thus a great potential to be an universal promising strategy targeting on solid tumor synergistic immunotherapy via co-operation with TCL-based vaccine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available